ReviewFrontiers in immunology2026
Pediatric leukemia: origins, pathogenesis, the role of microenvironment and immunological modulation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia remains the most commonly diagnosed pediatric cancer worldwide. Over the last decade, advances in therapy have significantly improved survival rates; however, treatment outcomes are still unsatisfactory for many patients. Further progress requires a comprehensive understanding of disease biology, including the hematopoietic process, mechanisms of leukemia initiation and progression, the genetic mutations involved, and the cell types that constitute the pre-leukemic and leukemic niches and interact with their microenvironment. Particular attention should be paid to the role of inflammation and immune modulation in the development of this childhood malignancy. Hematopoiesis occurs in three waves, and several hematopoietic niches are involved in cell development and maturation. In these locations, primary pre-leukaemic clones arise prenatally, yet only a subset of cases progress to overt leukemia after birth. In most patients, malignant progression is associated with the acquisition of secondary mutations, which may result from inflammation or exposure to specific infectious agents. Microenvironmental factors play a critical role in this process. Cross-talk between niche components and emerging leukaemic cells gradually shapes a microenvironment that favors malignancy. Extensive remodeling of this niche is driven by structural alterations, deregulation of signaling pathways essential for proper cell function and disturbances in the secretion of immunological factors, thereby creating a supportive and protective environment for leukemia progression. A detailed understanding of fetal hematopoiesis in the context of leukemia, and of how immunomodulatory factors and inflammatory mediators influence disease development, is crucial for improving therapeutic efficacy. This review provides an in-depth overview of these phenomena and, in addition to core information on pediatric leukemia, summarizes recent advances in elucidating its origin and pathogenesis, as well as emerging diagnostic and therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.